Glenmark Pharmaceuticals has informed that it has attached a media release on 1st June 2021 titled ‘Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg ‘which is self?explanatory.
The above information is a part of company’s filings submitted to BSE.